Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
Date:5/18/2010

p> Income from operations was RMB30.9 million (US$4.5 million) for the first quarter of 2010, which represented a decrease of 49.5% from RMB61.1 million for the same period in 2009.

Income tax expense for the first quarter of 2010 was RMB1.3 million (US$0.2 million), which was primarily comprised of the tax expense of RMB7.9 million (US$1.2 million) relating to our profitable subsidiaries. This amount was offset by recognition of tax credits of RMB5.8 million (US$0.8 million) relating to tax losses of certain subsidiaries.

Net income attributable to Simcere was RMB20.5 million (US$3.0 million) for the first quarter of 2010, compared to RMB48.2 million for the same period in 2009. Net margin, representing net income divided by total revenue, was 4.5% for the first quarter of 2010, compared to 10.9% for the first quarter of 2009.

Basic and diluted earnings per American Depository Share ("ADS") for the first quarter of 2010 were RMB0.37 (US$0.05) and RMB0.36 (US$0.05), respectively. One ADS represents two ordinary shares of the Company.

As of March 31, 2010, the Company had cash, cash equivalents and restricted cash of RMB332.4 million (US$48.7 million), compared to RMB458.1 million as of December 31, 2009'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Simceres Diosmectite API Passes EU-GMP Inspection
2. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
3. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
4. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
7. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
8. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
9. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
11. Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... DIEGO, Calif. and RESEARCH TRIANGLE PARK, N.C. ... (Nasdaq: OREX ), a biopharmaceutical company focused on ... a global provider of drug development and manufacturing services, ... Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as ...
... Inc. (Headquarters: Woodcliff Lake, New Jersey , Chairman and CEO: Hajime Shimizu , "Eisai") today announces ... (Headquarters: Baltimore, Maryland , Director: John Griffin , M.D., "BSI") related to Eisai,s GCPII (glutamate carboxypeptidase ... ... , ...
Cached Medicine Technology:Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 2Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 3Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 4Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 5Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 2Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 3
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... , PITTSBURGH, Sept. 22 Precision ... Sean McDonald received the Smart Business Magazine 2009 Pacesetters Award. ... Greater Pittsburgh area who are setting the pace for the ... the impact of their influence in the community-at-large as well ...
... , , , , ... daily syndicated show hosted by cardiac surgeon and health expert Dr. Mehmet Oz, ... clinic at the Reliant Convention Center in Houston, Texas on Saturday September 26, ... of basic health insurance. Dr. Oz will participate in the event and ...
... is too focused on new drug development, while not enough ... in knowledge likely to have the biggest impact on combating ... policy expert says, adding that a major shift in research ... the coming wave of cancer cases. Professor Richard Sullivan ...
... , , RANDOLPH, Mass., Sept. 22 ... to serving individuals with Autism Spectrum Disorders (ASD), today released its ... and adolescents with ASD ever published. , , ... information about the myriad treatments available for ASD," said Susan M. ...
... ... John Conlon, vice president of the company,s Hoosier Region, with one of its two Heartland ... ... America honored John Conlon, vice president of the company,s Hoosier Region, with one of ...
... ... Pediatric Speech Therapy Partnership , ... Atlanta, GA (PRWEB) September 22, 2009 -- Cobb Pediatric Therapy Services, a ... pleased to announce that Travis Consulting, LLC is now operating as its subsidiary, offering ...
Cached Medicine News:Health News:Precision Therapeutics President and CEO Sean McDonald Recipient of 2009 Pacesetters Award 2Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 2Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 3Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 4Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 5Health News:Expert calls for new cancer research priorities 2Health News:Expert calls for new cancer research priorities 3Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 2Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 3Health News:Conlon Wins Life Care's Heartland Division President's Award 2Health News:Cobb Pediatric Therapy Services Joins Forces with Travis Consulting, LLC to Offer Expanded Services Across the U.S. 2
... Retractor System represents the most widely ... Its wide array of retraction components ... versatile system for multi-directional exposure of ... are available for specific procedures: IMA ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... real-time PCR analysis of gene expression ... LightCycler 480 System combines amazing speed ... the needs of a broad range ... including array validation, gene-knockdown studies, and ...
... PyGON now offers a very unique product series, ... alarm dialing for refrigerators and freezers. This is ... only a phone line. With our VM500 solution ... to 128 points over one phone line. The ...
Medicine Products: